Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 20th Preview)
-
Regulatory approvals in rare bone disease
The FDA has approved Regeneron’s activin A-targeting monoclonal antibody garetosmab (Pasatru) for fibrodysplasia ossificans progressiva (FOP), completing a decades-long development effort and expanding the small set of disease-modifying options for this ultrarare disorder. The approval is the second for FOP and is notable for showing clinically meaningful reductions in clinician-assessed flare-ups in adults. Pasatru was cleared for use in adults and administered intravenously every four weeks. In the Optima phase 3 program, both high- and low-dose regimens reduced new bone lesion formation by about 90% over 56 weeks, while the high-dose arm reduced painful localized inflammation by 89% versus placebo. An independent data monitoring committee recommended switching placebo patients to Pasatru after interim results. The decision follows a late-stage readout that underscored the biological role of activin A in the FOP disease cascade, as Regeneron scientists identified the pathway target more than a decade ago. With only an estimated ~220 adult patients in the U.S., the label has outsized impact for a community that has historically relied on symptomatic care.
-
Personalized mRNA cancer vaccines gain Phase 3 milestone
Merck and Moderna announced a randomized Phase 3 success for their personalized neoantigen mRNA vaccine intismeran autogene (intismeran) combined with Keytruda in adjuvant melanoma. The companies said the regimen met its primary endpoint of recurrence-free survival improvement and also improved distant metastasis-free survival, setting up potential regulatory discussions. In the interim analysis described in public statements, the therapy reduced the odds of recurrence or death versus control and produced a separation in key outcomes intended for an approval path. The companies characterized the results as statistically significant and clinically meaningful, while noting that full details will follow in scientific publication processes. The readout marks a “first randomized Phase 3” aimed at definitively validating personalized neoantigen vaccines in melanoma, a program that ties platform manufacturing and patient-specific neoantigen selection to conventional checkpoint therapy. If confirmed after full datasets, it could reshape how developers design next-generation autogene-style vaccine trials across solid tumors.
-
First-line targeted therapy for EGFR exon 20 insertions clears Phase 3 hurdle
In a pivotal Phase 3 trial, sunvozertinib outperformed chemotherapy as first-line treatment in advanced non–small-cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The study randomized 324 patients 1:1 to sunvozertinib or carboplatin–pemetrexed, with progression-free survival assessed by blinded independent central review. Sunvozertinib delivered a median progression-free survival of 10.3 months versus 7.5 months for chemotherapy (hazard ratio 0.65, p<0.001). The objective response rate was 58.9% with sunvozertinib compared with 31.1% with chemotherapy, and at 12 months PFS was reported in 46.1% of patients versus 26.7% under chemotherapy. The safety profile included higher rates of grade 3 or worse adverse events for sunvozertinib (75.5% vs. 56.7%), with grade 3 or higher creatine kinase elevations, diarrhea, and anemia reported as common. No deaths were attributed to investigational drug-related adverse events. The results were published at NEJM.org following funding by Dizal Pharmaceuticals.
-
Big deal in rare bone disease – BioMarin buys Alesta’s ALE-1
BioMarin agreed to acquire Alesta Therapeutics BV’s lead oral small-molecule candidate ALE-1 in a transaction valued at $275 million upfront and up to $490 million with milestones. The asset targets mineralization biology for hypophosphatasia, reinforcing BioMarin’s strategy in skeletal disease rather than expanding into unrelated therapeutic areas. ALE-1 is in phase I/IIa for hypophosphatasia and is positioned as an oral option in a space that has increasingly valued convenience and scalable dosing. Analysts described the deal as consistent with BioMarin’s continued interest in the inorganic pyrophosphate (PPi) pathway. The acquisition follows BioMarin’s earlier decision to discontinue BMN-401 (INZ-701), which also targeted the PPi axis, highlighting how companies recycle platform hypotheses but can alter programs based on emerging clinical or development signals.
-
Car T development pivot after toxicity in solid-tumor program
Chimeric Therapeutics halted its phase I/II study of CHM-2101, an autologous cadherin-17-targeted CAR T for gastrointestinal cancers, after a second patient at the highest dose level experienced dose-limiting toxicities. The company said it will stop development of CHM-2101 in its current form. Chimeric also announced a strategic pivot toward an early-stage in vivo CAR program aimed at the same antigen, reflecting an attempt to redesign the therapeutic context to improve tolerability or operational risk. The decision underscores the narrow tolerability windows that often define solid-tumor CAR T programs. For investors and investigators, the shift is a direct signal that CDH17 targeting remains a high-interest biology, but that the current autologous ex vivo manufacturing and dosing scheme will not continue as tested.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.